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Abstract
Recent evidence suggests that an initial barrier to the emergence of tumours is a DNA damage response that evokes a
counter-response which arrests the growth of, or eliminates, damaged cells. Early precursor lesions express markers of an
activated DNA damage response in several types of tumour, with a diminishing response in more advanced cancers. An
important marker of DNA damage is ATM which becomes phosphorylated (pATM) upon activation. We have investigated
pATM expression patterns in cultured keratinocytes, skin explants and a spectrum of pre-malignant to malignant
keratinocyte skin lesions by immunohistochemistry. We found that pATM was mainly localised to the Golgi apparatus,
which contrasts with its nuclear localisation in other tissues. Upon UV irradiation there is transient formation of pATM in
nuclear foci, consistent with recruitment to the sites of DNA damage. By immunohistochemistry we show pATM expression
in precancerous keratinocyte lesions is greater and predominantly nuclear when compared to the invasive lesions where
pATM is weaker and predominantly cytoplasmic. Our results are consistent with the hypothesis that the DNA damage
response acts as a barrier to cutaneous tumour formation, but also suggests that ATM expression in skin is different
compared to other tissues. This may be a consequence of the constant exposure of skin to UVR, and has implications for
skin carcinogenesis.
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Introduction
The integrity of genomic DNA is constantly under threat from
cytotoxic agents. DNA damage checkpoints ensure genomic
stability both by delaying cell cycle progression and by activating
repair processes, pathways essential for prevention of tumour
development. If the cell is damaged beyond repair then these
checkpoints can also participate in apoptosis to eliminate the
damaged cells. Central to the DNA damage response is the protein
kinase ATM, a member of the phosphatidyl inositol 3-kinase-like-
kinase (PIKK) family. ATM is required for transduction of the
DNA damage signal to downstream protein kinases essential for
the execution of cell cycle checkpoint arrest [1]. In an unsti-
mulated state, ATM is thought to exist as a homodimer in which
the kinase domain of one subunit faces the autophosphorylation
site of another [2]. Upon activation, ATM undergoes a con-
formational change that stimulates the kinase to phosphorylate
Ser1981 by intermolecular autophosphorylation (pATM), result-
ing in dissociation of the homodimer [2]. Several downstream
targets of pATM have been identified including p53, Mdm2,
E2F1, Chk2, Nbs1, histone H2AX, c-Abl and BRCA1. These, in
turn, are responsible for multiple downstream effects including
activation of the G1/S, S and G2/M checkpoints and DNA repair
activation. Activation of ATM and the downstream cell cycle
checkpoint kinases Chk1 and Chk2 constitute an important
mechanism for eliminating damaged cells early in precancerous
lesions [3]. DNA damage checkpoints might become activated in
the early stages of human tumorigenesis, leading to cell cycle
blockade or apoptosis, thereby hindering tumour progression.
Recent evidence suggests that an initial barrier to the emergence
of tumour cells is a DNA damage response that evokes a counter-
response responsible for eliminating damaged and potentially
dangerous cells [4,5]. In clinical specimens from different stages of
human tumours (including urinary bladder, breast, lung and
colon), the early precursor lesions (but not normal tissues), express
markers of an activated DNA damage response. These included
phosphorylated kinases ATM and Chk2, and phosphorylated
histone H2AX and p53.
As yet, no similar studies have been reported in cutaneous
squamous cell carcinoma (SCC), although Gorgoulis et al.
examined the DNA damage response in dysplastic naevi and
melanomas, as well as adjacent normal skin [3]. Non melanoma
skin cancers (NMSC), including cutaneous SCC, are the most
common human malignancies and cutaneous SCC provides an
ideal model in which to study the DNA damage response since
there exists a spectrum of stages in its development, from
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21271premalignant actinic keratosis through to carcinoma in situ
(Bowen’s disease), and invasive SCC. UVR is the principle
carcinogen implicated and there is overwhelming epidemiological
evidence to support an association between UV exposure and
SCC reviewed by Armstrong and Kricker, 2001 [6]. Solar
radiation, in particular the UVB component of the spectrum, is
known to induce mutations in genomic [7] and mitochondrial
DNA [8], which makes it the most important aetiological agent in
the development of NMSC [9].
UV-induced DNA damage is characterised by two main types of
lesions: cyclobutane pyrimidine dimers (CPDs) and (6–4) photo-
products. Translesional DNA synthesis by pol can lead to mis-
incorporation of nucleotides, resulting in genomic mutations which
may then lead to cancer [10]. The importance of effective DNA
repair is highlighted by the photosensitive inherited disorder
xeroderma pigmentosum (XP) in which patients have a defect in
nucleotide excision repair (NER)-associated genes and are sensitive
to UV exposure, with an increased susceptibility to NMSC [11].
Recent studies in mice transgenic for either a (6–4) photoproduct or
CPD photolyase gene, whose expression was targeted to basal
keratinocytes, revealed the importance of the removal of CPDs in
preventing NMSC [12]. Furthermore, transcriptome analysis
showed that the most prominent pathway induced by CPDs was
that associated with double strand break (DSB) repair. These results
imply that the conversion of unrepaired CPDs into dsDNA breaks
during DNA replication constitutes the principal source of UV-
mediated cytotoxicity [13]. ATM is believed to be predominantly
activated by DSBs, lesions that are highly genotoxic. Given that
UVR primarily induces DSBs [13], the aims of this study were to
investigate the expression of ATM and activated ATM (pATM) in
both normal skin as well as in the spectrum of premalignant actinic
keratosis (AK) to carcinoma in-situ (CIS) to invasive SCC lesions, to
see whether the model proposed by Bartkova et al. could be
extended to include cutaneous SCCs. It was also hypothesised that,
as skin is constantly exposed to UVB, there may be differences in
cutaneous / keratinocyte ATM function.
Results
pATM is localised to the Golgi apparatus in normal
human primary keratinocytes (NHPK) following UVB
irradiation
Normal human primary keratinocytes (NHPK) (derived from
skin obtained from a non UV exposed site in a 30-year-old
Caucasian woman), were irradiated with UVB and fixed at various
time points post-treatment. Cells were stained for pATM both
fluorescently and non-fluorescently (Figures 1 and 2). pATM in
untreated NHPK was present at specific peri-nuclear foci. At 30-
60 minutes post-UVB irradiation a significant proportion of
pATM is expressed in the nucleus. However, 2 hours post-UV no
Figure 1. pATM staining of Normal Human Primary Keratinocytes +/2 UVB. Cells were UVB irradiated (10 mJ/cm
2) and fixed at various
times post-UV with 4% PFA. Un-irradiated cells show cytoplasmic expression of pATM with more nuclear staining observed 30–60 minutes post-UV.
2 hours following UV irradiation pATM again assumes perinuclear and cytoplasmic expression.
doi:10.1371/journal.pone.0021271.g001
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once again found in its ‘resting position’ in the peri-nuclear and
cytoplasmic regions of the cell. The specific peri-nuclear pattern of
staining of pATM was postulated to represent localisation to the
Golgi apparatus. To test this, NHPK cells were fluorescently
labelled with both a Golgi specific marker (Giantin) and pATM
(Fig 3). This double labelling demonstrates co-localisation of
pATM to the Golgi apparatus. In untreated NHPK, pATM
localised predominantly to the Golgi apparatus, although between
30 minutes to 2 hours post-UV irradiation, pATM was addition-
ally visualised in the nucleus (consistent with the findings in Figs 1
and 2). Thus following UV, transient nuclear re-localisation of
pATM can be seen after 30 minutes which then returns to the
Golgi after 2 hours. The specificity of the pATM antibody used in
this study is demonstrated in Figure S1 where a Western blot of
the nuclear fraction of undamaged and UV irradiated normal
human primary keratinocytes is labeled with both pATM and
ATM antibodies. Following UV there is upregulation of nuclear
pATM 1 hour post-UV with levels returning to baseline
thereafter, and with no significant change in ATM expression.
pATM expression in acute vs. chronically UV exposed
normal skin differs, with greater nuclear expression seen
in the latter
pATM expression was examined in untreated and UVB
irradiated skin sections from explant organ culture. Normal skin
was obtained from both a non UV-exposed and UV-exposed site
in age- and sex-matched Caucasian subjects. Fig 4 shows
immunohistochemistry of normal non-UV exposed skin irradiated
with UVB. pATM expression can be seen in untreated skin which
most likely represents either background staining or a low level of
‘real’ staining. There is upregulation of pATM 30–60 minutes
post-UVB, in keeping with the well-documented rapid onset of
pATM activation in response to a damaging stimulus. The
upregulation of pATM was characterised by the visibly heavier
expression in some cells, but not all; this appeared to be more
prominent in the basal layers of the epidermis, presumably related
to the greater proliferative potential of basal keratinocytes.
Markedly increased expression at 1 and 4 hours post-UV with a
reduction at 8 hours was observed. By 16 and 24 hours post-UV,
only individual cells showed more intense staining compared to
background levels. pATM expression was predominantly localised
to the cytoplasm, particularly around the peri-nuclear region, with
relatively sparse staining in the nucleus, consistent with observa-
tions in NHPK.
The UV-induced pATM signal demonstrated by immunohis-
tochemistry is depleted by silencing of ATM expression. ATM in
human keratinocytes (PM1) was silenced using SiRNA (Dharma-
con) (Figure S2). Following UV irradiation there is upregulation of
pATM in the scrambled cell line with significant nuclear staining
after 1–2 hours. In contrast there is very little pATM seen in both
undamaged and UVB irradiated ATM silenced cells (Figure S3).
Figure 2. Fluorescent pATM staining of NHPK +/2 UVB. Same cells as in Fig 1 fluorescently labelled using DAPI (blue) to stain the nucleus.
pATM was fluorescently labelled with Alexa Fluor 568 (red) and cells visualised using confocal microscopy. Findings mirror those observed in Fig 1 - a
very specific pattern of cytoplasmic staining is seen; at 60 minutes following UVB there is more nuclear expression of pATM which is short-lived,
returning back to the cytoplasm after 2 hours.
doi:10.1371/journal.pone.0021271.g002
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e21271Figure 3. Confocal microscope image of fluorescently labelled NHPK +/2 UVB with pATM and Golgi specific marker. Fluorescently
labelled NHPK +/2 UVB (10 mJ/cm
2) with pATM-conjugated Alexa Fluor 568 (red), Golgi-specific antibody (Giantin) conjugated Alexa Fluor 488
(green), and nuclear DAPI staining (blue). There is co-localisation of pATM to the Golgi apparatus. 30 minutes to 2 hours post-UV there is transient
nuclear localisation of pATM.
doi:10.1371/journal.pone.0021271.g003
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pATM showed predominantly nuclear expression (Fig 5). This
suggested that chronic rather than acute UV exposure is required
as a stimulus for nuclear pATM expression even though UV
exposure in the short term leads to a transient increase in pATM
levels.
Figure 4. pATM expression in normal human skin +/2 UVB. Paraffin embedded normal skin (taken from a non-UV exposed site) was UV
irradiated (10 mJ/cm
2) and fixed with 4% PFA at various times post-UV, then stained with pATM antibody at various time points post-UV. pATM
expression can be seen in untreated skin with upregulation 30–60 minutes following UVB irradiation. pATM expression is predominantly cytoplasmic
and peri-nuclear.
doi:10.1371/journal.pone.0021271.g004
Figure 5. pATM expression in normal UV exposed skin (face). a) Negative control – no primary pATM Ab; b) pATM staining: predominantly
nuclear staining observed.
doi:10.1371/journal.pone.0021271.g005
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e21271Figure 6. Fluorescent pATM staining of PM1 (A) and Met1 (B) cells +/2 UV. PM1 and Met1 cells were UVB irradiated (10 mJ/cm
2) and fixed in
4% PFA at various times post-UV. Cells were then labelled with pATM conjugated with Alexa Fluor 568 (red) and counterstained with DAPI (blue).
(A) Note nuclear foci of pATM at 1 hour and 2 hours post-UV (white arrows) in PM1 cells. No nuclear expression of pATM observed in Met1 cells.
doi:10.1371/journal.pone.0021271.g006
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intraepithelial neoplasia differs from that in invasive
lesions
Investigation of pATM expression was extended to human skin
malignancies by examining representative samples from each stage
in SCC development.
(i) pATM in cell lines representing pre-invasive (PM1) and
invasive (Met1) SCC show greater nuclear expression in the
pre-invasive tissue. The cell lines PM1 and Met1 are derived
from the same patient, a 55 year old Caucasian renal transplant
recipient. The PM1 cell line was cultured from a dysplastic region
on the forehead and Met1 from an SCC on the dorsum of hand
which had metastasized; metastases were pathologically and
genetically confirmed to have come from the primary SCC on
the hand [14]. Cells were UVB irradiated and fluorescently
stained with pATM. It can be seen in Fig 6 that both PM1 and
Met1 cells have patterns of pATM expression similar to those seen
in the NHPK, i.e. focal cytoplasmic and peri-nuclear staining
consistent with Golgi localisation. No nuclear expression of pATM
is seen in the Met1 cell line though there does appear be some,
albeit very low levels, of pATM in the nucleus in the PM1 cell line,
particularly 2 hours post-UVB treatment. Since the PM1 cells
represent an early stage of tumorigenesis, this finding would be in
keeping with the proposal that there is an upregulation of DNA
damage response proteins in the nucleus in early carcinogenesis.
(ii) pATM in human skin samples representing sequential
keratinocyte neoplasia show greater, and predominantly
nuclear expression, in early lesions. In order to consolidate
these preliminary findings a series of AKs, CIS and SCC lesions
were analysed for pATM expression. Samples from each
pathologic category were identified through the histopathology
database and the histological diagnosis confirmed by re-
examination of the H&E sections by two independent observers
(RC and CH). AK sections were graded into three categories: AK
I, II and III, based on the degree of atypical keratinocytes in the
epidermis [15,16]. SCCs were also classified into well, moderately
and poorly differentiated tumours. Poorly differentiated tumours
have a worse prognosis with more than double the local
recurrence rate and triple the metastatic rate of well
differentiated SCC [17].
Methods of Analysis. The extent of pATM expression was
expressed as a percentage of positive cells with nuclear and
cytoplasmic expression recorded separately. This was categorised
as grade 1, .0–5%; grade 2, .5–25%; grade 3, .25–50%; grade
4, .50–75%; grade 5, .75–100%. Lesions were scored
independently by two observers (FI and CH) and a consensus
decision was reached in the case of any discrepancies (Table 1,
Fig 7). We compared nuclear and cytoplasmic pATM expression
using a paired t-test for matched data. pATM differences between
cytoplasm and nucleus were compared across two groups using the
rank sum test. pATM differences between cytoplasm and nucleus
were compared across three ordered groups using the
nonparametric test for trend across ordered groups developed by
Cuzick. In addition, pATM was reclassified as a binary variable
(#50% vs. .50%) (Table 2). Comparisons between nuclear and
cytoplasmic expression were made by comparing the discordant
pairs (McNemar’s chi-squared).
Comparison of Nuclear pATM. The majority of SCC
lesions had nuclear pATM expression of between 5 and 75% with
only 1/28 (3.6%) with .75% and 1/28 (3.6%) with #5%. There
was no significant difference in pATM nuclear expression
according to SCC differentiation status (p=0.44). Similarly for
AK lesions, there was no significant difference in pATM nuclear
expression between AK grades (p=0.44). The median pATM
nuclear levels decreased from AK (75–100%) to CIS (75–100%) to
SCC (25–50%) (p,0.001).
Comparison of cytoplasmic pATM. There was no
significant difference in pATM cytoplasmic expression according
to SCC differentiation status (p=0.80). Similarly for AK lesions,
there was no significant difference in pATM nuclear expression
between grades (p=0.88). The median pATM cytoplasmic
expression decreased from AK (75–100%) to CIS (75–100%) to
SCC (50–75%) (p=0.002).
Difference between nuclear and cytoplasmic pATM.
Within SCC lesions, pATM levels were higher in the cytoplasm
then the nucleus in 16/28 (57.1%) lesions; equivalent in 11/28
(39.3%) lesions and lower in 1/28 (3.6%) lesions (p-
value=0.0001).
Among well differentiated SCC lesions, pATM levels were
higher in the cytoplasm then the nucleus in 3/7 lesions; equal in
3/7 lesions and lower in 1/7 lesions (p-value=0.45). 2/7 lesions
Table 1. pATM protein expression by immunohistochemistry – results for individual AK, CIS and SCC lesions.
SCC CIS AK
Grade of pATM
protein expression Well Moderate Poor Total Total Grade I Grade II Total
.0–5% Nuclear 0 (0.0%) 0 (0.0%) 1 (14.3%) 1 (3.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Cytoplasm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
.5–25% Nuclear 2 (28.6%) 4 (28.6%) 2 (28.6%) 8 (28.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Cytoplasm 2 (28.6%) 0 (0.0%) 2 (28.6%) 4 (14.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
.25–50% Nuclear 3 (42.9%) 4 (28.6%) 3 (42.9%) 10 (35.7%) 2 (7.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Cytoplasm 2 (28.6%) 0 (0.0%) 1 (14.3%) 3 (10.7%) 1 (3.6%) 1 (9.1%) 1 (20.0%) 2 (12.5%)
.50–75% Nuclear 2 (58.6%) 5 (35.7%) 1 (14.3%) 8 (28.6%) 7 (25.0%) 1 (9.1%) 1 (20.0%) 2 (12.5%)
Cytoplasm 1 (14.3%) 9 (64.3%) 2 (28.6%) 12 (42.9%) 5 (17.9%) 2 (18.2%) 0 (0.0%) 2 (12.5%)
.75–100% Nuclear 0 (0.0%) 1 (7.1%) 0 (0.0%) 1 (3.6%) 19 (67.9%) 10 (90.9%) 4 (80.0%) 14 (87.5%)
Cytoplasm 2 (28.6%) 5 (35.7%) 2 (28.6%) 9 (32.1%) 22 (78.6%) 8 (72.7%) 4 (80.0%) 12 (75.0%)
Total 7 (100%) 14 (100%) 7 (100%) 28 (100%) 28 (100%) 11 (100%) 5 (100%) 16 (100%)
doi:10.1371/journal.pone.0021271.t001
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lesions had nuclear pATM .50% but cytoplasmic #50%
(p=1.0). Among moderately differentiated SCCs, pATM levels
were higher in the cytoplasm then the nucleus in 9/14 lesions;
equal in 5/14 lesions and was not lower in any lesions (p-
value=0.0006). 8/14 lesions had cytoplasmic pATM .50% but
nuclear #50%, whereas no lesions had nuclear pATM .50% and
cytoplasmic #50% (p=0.0078). Among poorly differentiated
SCCs, pATM levels were higher in the cytoplasm then the
nucleus in 4/7 lesions; equal in 3/7 lesions and was not lower in
any lesions (p-value=0.038). 3/7 lesions had cytoplasmic pATM
.50% but nuclear #50%, whereas no lesions had nuclear pATM
.50% but cytoplasmic #50% (p=0.25). In summary, the
difference in pATM between cytoplasm and nucleus was not
significantly different between differentiations in the SCC lesions
(p=0.45).
Among CIS lesions, pATM levels were higher in the cytoplasm
then the nucleus in 4/28 (14.3%) lesions; equal in 23/28 (82.1%)
lesions and lower in 1/28 (3.6%) lesions (p-value=0.16). 2/28
(7.1%) lesions had cytoplasmic pATM .50% but nuclear #50%,
whereas 1/28 (3.6%) lesions had nuclear pATM .50% but
cytoplasmic #50% (p=1.0).
Figure 7. pATM expression in lesional tissue – examples of scoring for nuclear (A) and cytoplasmic (B) staining.
doi:10.1371/journal.pone.0021271.g007
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then the nucleus in 1/16 (6.3%) lesions; equal in 11/16 (68.8%)
lesions and lower in 4/16 (25.0%) lesions (p-value=0.16). No
lesions had cytoplasmic pATM .50% but nuclear #50%,
whereas 2/16 (12.5%) lesions had nuclear pATM .50% but
cytoplasmic #50% (p=0.5). There were no significant differences
according to grade of AK.
Figs 8, 9, 10 show representative pATM stained sections of
AKs, CIS and SCC lesions respectively, with Fig 11 demonstrating
more clearly the overall differences in expression pattern that exist
between the histological spectrum of disease. AKs show predom-
inantly heavy nuclear expression of pATM which becomes
progressively less nuclear and more cytoplasmic as the lesion
evolves to more advanced SCC. It is also notable that, where
present, nuclear expression of pATM was detected in histologically
normal perilesional skin. This accords well with the observation
that pATM is also predominantly nuclear in normal skin from
chronically UV exposed sites, similar to the expression pattern
seen here in precancerous AKs and CIS.
Discussion
This is the first study to date to investigate the localisation and
behaviour of pATM in skin in an attempt to address the proposal
that an activated DNA damage response is an initial barrier to the
emergence of cutaneous SCC, as has been postulated for other
cancers [4,5]. Key findings from these studies show that in clinical
specimens from different stages of various other tumours that the
early precursor lesions, but not normal tissues, commonly express
markers of an activated DNA damage response. Genetic analyses
indicated that early in tumourigenesis (before genomic instability
and malignant conversion), human cells activate an ATR/ATM-
regulated DNA damage response network that delays or prevents
cancer. Data presented in this study provide evidence that the
DNA damage response is active in all pre-invasive lesions (AK and
CIS) but that this mechanism is overridden at a later point in the
evolution of cutaneous SCC.
In earlier studies, the pATM expression pattern reported in
precancerous lesions from tissues other than skin was predomi-
nantly nuclear, with expression levels diminishing in more
advanced lesions [4]. In skin we have found that even in the
presence of nuclear expression of pATM, precancerous AKs can
theoretically still progress to CIS given that a similar level of
nuclear pATM expression exists in both stages of skin cancer
development. A transition appears to occur between CIS and
SCC, with a significant loss of nuclear pATM expression seen in
the latter. Several preliminary conclusions may be drawn from
Figure 8. pATM expression in AK. A) Scored as nuclear 5 and cytoplasm 5; B) Scored as nuclear 4 and cytoplasm 3.
doi:10.1371/journal.pone.0021271.g008
Table 2. Summary of Nuclear vs. Cytoplasmic staining in AKs,
CIS and SCC.
Nuclear Cytoplasm
AK 16/16 14/16
CIS 26/28 27/28
SCC 9/28 21/28
Figures only include grade of protein expression of .50%.
doi:10.1371/journal.pone.0021271.t002
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PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e21271Figure 9. pATM expression in CIS. A) Scored as nuclear 5 and cytoplasm 5; B) Scored as nuclear 4 and cytoplasm 4.
doi:10.1371/journal.pone.0021271.g009
Figure 10. pATM expression in SCCs. A) Scored as nuclear 3, cytoplasm 4; B) Scored as nuclear 2, cytoplasm 4.
doi:10.1371/journal.pone.0021271.g010
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response in skin behaves differently to other tissues. The
predominance of pATM in the cytoplasm and Golgi apparatus
suggests alternative roles for the protein other than as a sensor of
DNA damage. Although the presence of ATM in cytoplasmic
compartments has been previously documented in other tissues
[18,19], it has not been reported to occur in skin and not at such
high levels in comparison with nuclear expression. This difference
in DNA damage response is perhaps not surprising given the
constant exposure of skin to UVR. Further evidence indicating the
unique nature of skin with regard to its environmental suscepti-
bility is also possibly reflected in the differences in distribution and
levels of pATM in acute versus chronically UV exposed skin (i.e.
cytoplasmic and nuclear respectively).
Expression of pATM in normal skin is both cytoplasmic
and nuclear
In proliferating cells ATM is predominantly nuclear, in keeping
with a role in DNA-damage recognition and cell cycle control. A
proportion of ATM is extranuclear ev e ni np r o l i f e r a t i n gc e l l sa n di s
predominantly cytoplasmic in post-mitotic cells [18,20–23]. The
extranuclear ATM in proliferating cells is primarily, if not entirely,
present in vesicles including peroxisomes and endosomes [19,24].
With regards to active, phosphorylated ATM (pATM), nearly all
studies report its presence in the nucleus in several tissue types
including breast, colon and bladder[ 4 ] ,i nk e e p i n gw i t hi t sr o l e
in sensing DNA damage. However, Wu et al, using subcellular
fractionation studies, demonstrated that a small proportion of activated
ATM was exported from the nucleus in a NEMO-dependent (NF-kB
essential modulator) manner in HEK293 cells [25]. All reports of the
cytoplasmic localisation of ATM are from studies involving the use of
tissues and cell lines of non-cutaneous origin, and the subcellular
localisation of ATM has not been previously reported in skin. A
significant proportion of the active,phosphorylated form, pATM, is
also extranuclear, as shown in this study, a finding not previously
reported in skin and rarely addressed in non-cutaneous tissue.
Cytoplasmic pATM is localised to the Golgi apparatus
and is transiently expressed in the nucleus upon UV
irradiation
In NHPK monolayer cells fluorescently labeled with both pATM
and a Golgi specific marker, pATM co-localises to the Golgi apparatus
(Fig 3). Upon UV irradiation there is transient expression of pATM in
nuclear foci consistent with its recruitment to the sites of DNA damage.
Previous studies of pATM expression have reported its presence in the
nucleus in several tissue types including breast, colon and bladder [4],
in keeping with its role in sensing DNA damage.
Possible role of cytoplasmic pATM in skin
The results presented here suggest that the DNA damage
response in skin may be different compared to other tissues and
that pATM could have other functions. This may be a result of the
Figure 11. Overall pattern of pATM expression observed in spectrum of AK / CIS / SCC. This demonstrates greater proportion and
increased intensity of nuclear staining of earlier lesions i.e. AK (a) and CIS (b) compared to less extensive and weaker nuclear staining in more
advanced SCC (c).
doi:10.1371/journal.pone.0021271.g011
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for skin carcinogenesis. It is likely that nuclear pATM is involved
in the DNA damage response and that cytoplasmic pATM may
have other roles. A number of additional functions other than its
role in DNA damage have previously been proposed for ATM
though no clear understanding of these functions has been fully
established. ATM associates with b-adaptin in cytoplasmic vesicles
(in human lymphoblasts) which suggests a role in intracellular
transport mechanisms [24]. Zhang et al. show that ATM is an
interacting partner of CKIP-1 (casein kinase-2 interacting protein),
a protein implicated in muscle differentiation, regulation of cell
morphology and actin cytoskeleton. Although CKIP-1 is localised
both in the nucleus and the plasma membrane, only plasma
membrane-localised CKIP could form a complex with ATM and
recruited nuclear ATM protein to the plasma membrane,
including the phosphorylated form [26].
Molecular linkage between ATM and NF-kB signalling has also
been shown [25], with the NF-kB family of transcription factors
regulating genes involved in development, immune responses, cell
migration and apoptosis [27]. The observation by Yang and
Kastan that insulin enhances the activity of ATM kinase supports
a more general signalling function for ATM [28]. They provide
evidence that the kinase activity of ATM is also activated by
insulin through a non-DNA damage signalling pathway. It should
be noted that none of these studies involve the use of cutaneous
tissue. Finally, the role of ATM in vesicular structures has been
postulated to represent a specialised antioxidant system responsible
for detoxifying reactive oxygen intermediates although this is
speculative [23].
DNA damage response and tumour progression in
squamous cell carcinogenesis
Given that keratinocytes are under constant exposure to UVR,
the most important skin carcinogen, it is possible that the skin has
adapted to this very situation. The presence of pATM in the
cytoplasm, in addition to its DNA damage sensing role in the
nucleus, may act to further protect the keratinocyte, perhaps via a
cell signalling mechanism discussed above. With regard to
expression patterns of pATM in tumours, it can be seen that
early pre-invasive lesions - AK and CIS - express pATM to a
significantly greater extent than SCCs. This is in keeping with the
model proposed by Bartkova at al. that the DNA damage response
acts as a barrier for tumour progression.
In contrast to the nuclear localisation of pATM in premalignant
lesions (Figs 8 and 9) and in chronically UV exposed normal skin
(Fig 5), pATM is cytoplasmic in normal skin from a non-UV
exposed site (Fig 4), suggesting that chronic rather than acute UV
exposure is required as a stimulus for nuclear pATM expression
even though UV exposure in the short term leads to a transient
increase in pATM levels as seen in Fig 4, albeit in the cytoplasm.
The reduced nuclear expression of pATM in SCCs compared with
precancerous lesions, suggests that other oncogenic stresses have
overcome this response. One explanation is that mutations
compromising the DNA damage response pathway, such as
defects in pATM and its downstream effector molecules might
allow cell proliferation and tumour progression.
There remain many unanswered questions to be addressed in
future studies. pATM is consistently highly expressed in AKs and
CIS, and it is unclear why some lesions progress and others do not.
It is likely that that there are additional defects in cell cycle arrest,
senescence and apoptosis which could be investigated such as
cyclin E, Cdc25A and E2F1, to examine promotion of
unscheduled S-phase entry [29,30], as well as ATR, H2AX,
phosphorylated forms of p53 and activated Chk1/2. In addition it
is known that about one quarter of AKs regress [31] and this
would be an interesting subset of lesions to investigate in this
context. What is also not clear is whether early SCCs that
apparently arise de novo without clinical or histological evidence of
AK or CIS behave in a similar manner to AKs and CIS or
whether they fail to mount a significant DNA damage response
from the outset. Such studies may ultimately identify important
diagnostic, prognostic and therapeutic biomarkers for improved
skin cancer prevention and treatment.
Materials and Methods
Antibodies
We used primary antibodies against Ser 1981-phosphorylated
ATM (Rockland), ATM (Abcam), Lamin A (Abcam), Actin
(Abcam) and Giantin Golgi marker (Abcam). Secondary antibod-
ies used for immunofluorescence included Alexa Fluor 568 and
488 (Molecular Probes). Secondary antibodies used for Western
blotting were horseradish peroxidase-conjugated rabbit anti-
mouse (Dako).
Immunohistochemistry
Tumours were obtained from archival tissue banks in the
histopathology department at Barts and The London NHS Trust.
Ethics approval for the study of the molecular pathogenesis of non-
melanoma skin cancers was gained by the Tissue Research
Subcommitee of the East London and The City Health Authority
Ethics. Written consent was obtained from all participants of this
study. All sections used in this study were examined by Professor
Rino Cerio (Professor of dermatopathology) and graded histolog-
ically. Control tissue was obtained directly from skin belonging to
a 30 year old Caucasian female, from a non UV-exposed site,
following abdominal reduction surgery. Normal UV exposed skin
was obtained from an aged matched Caucasian female from the
face. The skin was immediately prepared by removing connective
tissue and subcutaneous fat, washed in warm sterile PBS and fixed
with 4% PFA overnight. For UVB treated skin, sections were
irradiated with 10 mJ/cm
2 UVB. Pre-warmed E4+F12+RM+
media was then added (see below) and the tissue left at 37uC till the
appropriate time for fixation post-UV, then immediately paraffin
embedded for sectioning. Indirect immunoperoxidase staining on
de-paraffinised tissue was performed using the VectastainH
Universal Elite ABC kit (Vector laboratories) and counterstained
with haematoxylin. The immunostaining patterns were evaluated
by two independent observers (FI and Dr Catherine Harwood)
and the grade of protein expression scored as follows: 1, .0–5%;
2, .5–25%; 3, .25–50%; 4, .50–75%; 5, .75–100%
Fluorescent and non-fluorescent immunocytochemistry
All monolayer cells were fixed with paraformaldehyde and
permeabilised with 0.1% Triton X-100. 0.2% fish skin gelatine
was used as a blocking agent followed by incubation with the
primary antibody and secondary antibodies. Where more than one
primary antibody was used in a single experiment, the relevant
secondary antibody was added directly afterwards, then an
additional blocking step included prior to incubation with the
second set of primary and secondary antibodies. DAPI was used as
a nuclear counter stain. Signal was visualised by fluorescent
confocal microscopy (Carl Zeiss, Jena, Germany) and analysed
using LSM 5 image examiner software. Cells non-fluorescently
labelled were prepared for staining in the same way as for those
fluorescently stained with regards to the permeabilisation, blocking
and primary antibody steps described but this was then followed
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Cell culture
Keratinocyte-derived cell lines were grown in a mixture of 3
parts DMEM and 1 part Hams F12 medium with 10% FCS and
the addition of various mitogens (RM+). 4 ml of RM+ concentrate
was added to 440 ml of keratinocyte base medium to give final
concentrations of Hydrocortisone 0.4 mg/ml, Cholera toxin
10
210 M, Transferrin5 mg/ml, Liothyronine 2610
211 M, Ade-
nine 1.8610
24 M, Insulin 5 mg/ml, Epidermal Growth Factor
10 ng/m. Defined Keratinocyte serum-free media (GibcoH) was
used for the growth of primary human keratinocyte cells. Cells
were grown at 37uCi n5 %C O 2 UVB irradiation of cells was
carried out using a CL-1000 ultraviolet cross linker (UVP) fitted
with F8-T5 UV-B lamps with peak output at 312 nm, and a single
dose of 10 mJ/cm
2 used.
Western Blotting
Cells were washed with PBS, collected by scraping and lysed in
RIPA buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1% Nonidet P-
40, 0.05% sodium deoxycholate, 1% SDS and Roche protease
inhibitor cocktail). Protein quantification was carried out using
Bradford protein assay (Perbio Science UK). The resulting protein
extracts were then separated by SDS-polyacrylamide gel electro-
phoresis and electroblotted onto nitrocellulose membranes.
Reactive proteins were visualized by chemiluminescence with
ECL plus (Amersham).
Nuclear fractionation
All steps were performed on ice or at 4uC. Cells were collected
and washed with ice-cold PBS then nuclei were isolated by
Dounce homogenization in CaRSB buffer (10 mM NaCl,
1.5 mM CaCl2, 10 mM Tris-Cl, pH 7.5) and MS buffer
(210 mM Mannitol, 70 mM sucrose, 5 mM EDTA, 5 mM
Tris-Cl, pH 7.6). The homogenate was centrifuged at 800 g for
5 minutes. The nuclear pellet was washed with MS buffer, re-
pelleted and resuspended in RIPA buffer with protease inhibitor
cocktail.
RNA interference
Cells were transfected with siRNA using HiPerFect (Qiagen)
according to the manufacturer’s instructions. Optimisation of the
siRNA protocol was performed using siGLO Cyclophilin B
positive control siRNA (Dharmacon). PM1 cells were silenced
with ON-TARGETplus SMART pool human ATM siRNA or
ON-TARGETplus non-targeting pool negative control siRNA
(both from Dharmacon). Transfection complexes were removed
after 24 hours and cells incubated in fresh medium for a further
48 hours before UV irradiation and harvesting for Western blot
analysis or fixing for immunocytochemistry.
Supporting Information
Figure S1 Western blot of NHPK nuclear fraction +/2
UV for pATM and ATM. Nuclear extracts of NHPK were
prepared with undamaged and UVB irradiated lysates examined
for pATM and ATM expression using Lamin A as a nuclear
loading control.
(TIF)
Figure S2 Western blot of Scrambled and ATM silenced
PM1 cells +/2 UV with pATM antibody. ATM in human
keratinocytes (PM1) was silenced using SiRNA (Dharmacon).
pATM antibody was directed against both undamaged and UVB
irradiated scrambled and ATM silenced cells.
(TIF)
Figure S3 Immunohistochemistry of Scr and ATM
silenced PM1 cells +/2 UV with pATM. Both the scrambled
and ATM silenced cells were plated onto glass coverslips, treated
with UVB (10 mJ/cm2) and fixed at 1, 2 and 4 hours post-UVB.
The cells were then labelled with pATM.
(TIF)
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